Novo Nordisk (NVO)

Executive Summary

Novo Nordisk A/S is a global leader in diabetes and obesity care, driven by its GLP-1 receptor agonist portfolio including blockbusters Ozempic, Wegovy, and Rybelsus. The company also has a strong pipeline in rare diseases and cardiovascular indications. In 2025, Novo Nordisk reported robust sales growth, driven by soaring demand for Wegovy and expansion into new markets. The company is investing heavily in manufacturing capacity and next-generation therapies like oral GLP-1 formulations and combination treatments (e.g., CagriSema). Key upcoming catalysts include the FDA decision for oral semaglutide in obesity, which could unlock a large patient segment, and Phase 3 data for CagriSema in obesity, potentially offering superior efficacy. Additionally, the broader label expansion of semaglutide for cardiovascular indications or heart failure could further drive revenue. Despite competitive pressure from Eli Lilly's tirzepatide, Novo Nordisk's first-mover advantage, strong clinical data, and manufacturing scale position it well for sustained growth. The company maintains a high conviction score given its dominant market position and pipeline breadth.

Upcoming Catalysts (preview)

• Q3 2026FDA Decision on Oral Semaglutide (Rybelsus) for Obesity85% success
• Q4 2026Phase 3 Data for CagriSema (Cagrilintide + Semaglutide) in Obesity75% success
• H1 2027Semaglutide Label Expansion for Cardiovascular Outcomes (e.g., Heart Failure)90% success